Catalog |
name |
Description |
price |
R-C-1931 |
EHT5372 CAS :1425945-63-6 |
EHT 5372 is a highly potent and selective inhibitor of DYRK isfamily kinases with IC50s of 0.22,0.28,10.8,93.2,22.8,88.8,59.0,7.44,221 nM for DYRK1A,DYRK1B,DYRK2,DYRK3,CLK1,CLK2,CLK4,GSK-3α,GSK-3β. |
price> |
R-C-1950 |
STK321130 CAS:923562-23-6 |
STK321130(FLT3-IN-2)is potent FLT3 inhibitor. |
price> |
R-C-1974 |
BMS-986142 CAS :1643368-58-4 |
BMS-986142 is a potent,selective,reversible BTK inhibitor.BMS-986142 shows BTK IC50=0.5nM;human WB IC50=90 nM.In molecule of BMS-986142,two atropisomeric centers were rotationally locked to provide a single,stable atropisomer,resulting in enhanced potency and selectivity as well as a reduction in safety liabilities.With significantly enhanced potency and selectivity, excellent in vivo properties and efficacy,and a very desirable tolerability and safety profile,BMS-986142 was advanced into clinical studies. |
price> |
R-C-1985 |
Alflutinib (AST2818) mesylate CAS:2130958-55-1 |
Alflutinib(AST2818)mesylate is a third-generation epidermal growth factor receptor(EGFR)inhibitor that inhibits both EGFR-sensitive mutations and T790M mutations.Alflutinib(AST2818),primarily metabolized by CYP3A4,is also a potent CYP3A4 inducer with EC50 of 0.25μM. |
price> |
R-C-1998 |
Sitravatinib CAS: 1123837-84-2 |
Sitravatinib(MGCD516)is an orally bioavailable receptor tyrosine kinase (RTK)inhibitor with IC50s of 1.5nM,2nM,2nM,5nM,6nM,6nM,8nM,0.5nM,2nM,5nM,and 9 nM for Axl,MER,VEGFR3,VEGFR2,VEGFR1,KIT,FLT3,DDR2,DDR1,TRKA,TRKB,respectively. Sitravatinib shows potent single-agent antitumor efficacy and enhances the activity of PD-1 blockade through promoting an antitumor immune microenvironment. |
price> |
R-C-2017 |
BMS-986165 CAS:1609392-27-9 |
BMS-986165 is a Highly Potent and Selective Allosteric Inhibitor of TYK2.BMS-986165 Blocks Il-12,IL-23 and type I Interferon Signaling and Provides for Robust Efficacy in Preclinical Models of Inflammatory Bowel Disease. |
price> |
R-C-2032 |
AZD-3463 CAS:1356962-20-3 |
AZD3463 is a novel orally bioavailable ALK inhibitor with Ki of 0.75nM, which also inhibits IGF1R with equivalent potency.AZD3463 suppresses cell viability by inducing both cell apoptosis and autophagy. |
price> |
R-C-2040 |
Mobocertinib (TAK788) CAS:1847461-43-1 |
Mobocertinib(TAK788,AP32788)an investigational TKI,is a potent, selective preclinical inhibitor of epidermal growth factor receptor (EGFR)and HER2 mutations.Mobocertinib(TAK788)is an antineoplastic agent. |
price> |
R-C-2053 |
ALW-II-41-27 CAS:1186206-79-0 |
ALW-II-41-27 is a Eph receptor tyrosine kinase inhibitor.pharmacologic inhibition of EPHA2 by the small-molecule inhibitor ALW-II-41-27 decreased both survival and proliferation of erlotinib-resistant tumor cells and inhibited tumor growth in vivo.ALW-II-41-27 was also effective in decreasing viability of cells with acquired resistance to the third-generation EGFR TKI AZD9291. Collectively,these data define a role for EPHA2 in the maintenance of cell survival of TKI-resistant,EGFR-mutant lung cancer and indicate that EPHA2 may serve as a useful therapeutic target in TKI-resistant tumors. |
price> |
R-C-2057 |
Ki20227 CAS:623142-96-1 |
Ki20227 is an orally active and highly selective inhibitor of c-Fms tyrosine kinase(CSF1R)with IC50 of 2 nM,12nM,451 nM and 217 nM for c-Fms,vascular endothelial growth factor receptor-2(KDR/VEGFR-2),stem cell factor receptor(c-Kit),and platelet-derived growth factor receptor beta(PDGFRβ). |
price> |